{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "11",
                "@year": "2023",
                "@timestamp": "2023-07-11T17:14:53.000053-04:00",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2022",
                "@month": "10"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": {
                "xocs:funding-agency-matched-string": "F. Hoffmann-La Roche",
                "xocs:funding-agency": "F. Hoffmann-La Roche",
                "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100007013",
                "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"
            },
            "xocs:funding-addon-generated-timestamp": "2022-09-13T12:17:57.749Z",
            "xocs:funding-text": "This work was supported by F. Hoffmann-La Roche , Switzerland (no grant number). F. Hoffmann-La Roche participated in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60000291",
                            "@country": "deu",
                            "city": "Munich",
                            "organization": [
                                {"$": "University Hospital Munich"},
                                {"$": "Department of Obstetrics and Gynecology"},
                                {"$": "Breast Center and CCC Munich"},
                                {"$": "LMU"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60000291",
                                    "@dptid": "100304049"
                                },
                                {"@afid": "60028717"}
                            ],
                            "@affiliation-instance-id": "S2059702922001892-16941119df3b0bd33fe1753fc8027261",
                            "ce:source-text": "University Hospital Munich, Department of Obstetrics and Gynecology, Breast Center and CCC Munich, LMU, Munich, Germany",
                            "@dptid": "100304049"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "R.",
                                "ce:initials": "R.",
                                "ce:surname": "Wuerstlein",
                                "ce:indexed-name": "Wuerstlein R."
                            },
                            "@seq": "1",
                            "@author-instance-id": "S2059702922001892-84bb09ffefd8388c2c0337d5a05b9ff2",
                            "ce:initials": "R.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wuerstlein",
                            "@auid": "35489598700",
                            "ce:indexed-name": "Wuerstlein R."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United Kingdom",
                            "@afid": "60009797",
                            "@country": "gbr",
                            "city": "London",
                            "organization": {"$": "Guy's Hospital and Sarah Cannon Research Institute"},
                            "affiliation-id": {"@afid": "60009797"},
                            "@affiliation-instance-id": "S2059702922001892-ca5418866b75aacf64a2bd0b618d947e",
                            "ce:source-text": "Guy's Hospital and Sarah Cannon Research Institute, London, UK"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "P.",
                                "ce:initials": "P.",
                                "ce:surname": "Ellis",
                                "ce:indexed-name": "Ellis P."
                            },
                            "@seq": "2",
                            "@author-instance-id": "S2059702922001892-5d48432f8e98545ea1a47e9819363c6a",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Ellis",
                            "@auid": "16214959300",
                            "ce:indexed-name": "Ellis P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Italy",
                            "@afid": "60070526",
                            "@country": "ita",
                            "city": "Candiolo",
                            "organization": [
                                {"$": "Candiolo Cancer Institute"},
                                {"$": "FPO-IRCCS"}
                            ],
                            "affiliation-id": {
                                "@afid": "60070526",
                                "@dptid": "114278866"
                            },
                            "@affiliation-instance-id": "S2059702922001892-95d796db6281fd5909fc622e9c968882",
                            "ce:source-text": "Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy",
                            "@dptid": "114278866"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "F.",
                                "ce:initials": "F.",
                                "ce:surname": "Montemurro",
                                "ce:indexed-name": "Montemurro F."
                            },
                            "@seq": "3",
                            "@author-instance-id": "S2059702922001892-72af808463d5473bd0bcbfc0f02fec7e",
                            "ce:initials": "F.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Montemurro",
                            "@auid": "35187447200",
                            "ce:indexed-name": "Montemurro F."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Spain",
                            "@afid": "60022336",
                            "@country": "esp",
                            "city": "Zaragoza",
                            "organization": {"$": "Miguel Servet University Hospital and Aragon Health Research Institute (IISA)"},
                            "affiliation-id": [
                                {"@afid": "60022336"},
                                {"@afid": "60103289"}
                            ],
                            "@affiliation-instance-id": "S2059702922001892-421ac9670259caef4920e77ca69b79cb",
                            "ce:source-text": "Miguel Servet University Hospital and Aragon Health Research Institute (IISA), Zaragoza, Spain"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "A.",
                                "ce:initials": "A.",
                                "ce:surname": "Antón Torres",
                                "ce:indexed-name": "Antón Torres A."
                            },
                            "@seq": "4",
                            "@author-instance-id": "S2059702922001892-70f8aa024201c34f23e651e56bc89249",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Antón Torres",
                            "@auid": "6602294525",
                            "ce:indexed-name": "Anton Torres A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "France",
                            "@afid": "60027386",
                            "@country": "fra",
                            "city": "Villejuif",
                            "organization": {"$": "Institut Gustave Roussy"},
                            "affiliation-id": {"@afid": "60027386"},
                            "@affiliation-instance-id": "S2059702922001892-5938093f535fce4f943f8c5b550f9b1b",
                            "ce:source-text": "Institut Gustave Roussy, Villejuif, France"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S.",
                                "ce:initials": "S.",
                                "ce:surname": "Delaloge",
                                "ce:indexed-name": "Delaloge S."
                            },
                            "@seq": "5",
                            "@author-instance-id": "S2059702922001892-019e99a23617cdf2be4f78941177eff0",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Delaloge",
                            "@auid": "6701521265",
                            "ce:indexed-name": "Delaloge S."
                        }]
                    },
                    {
                        "affiliation": {
                            "@afid": "60021615",
                            "city": "Nangang, Harbin",
                            "organization": {"$": "Harbin Medical University Cancer Hospital"},
                            "affiliation-id": {"@afid": "60021615"},
                            "@affiliation-instance-id": "S2059702922001892-5f804dfaac07703f4a7de08b69ed1d65",
                            "ce:source-text": "Harbin Medical University Cancer Hospital, Nangang, Harbin"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "Q.",
                                "ce:initials": "Q.",
                                "ce:surname": "Zhang",
                                "ce:indexed-name": "Zhang Q."
                            },
                            "@seq": "6",
                            "@author-instance-id": "S2059702922001892-8e5fe126cd0c58f65a90854ae4b6a408",
                            "ce:initials": "Q.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Zhang",
                            "@auid": "58374985400",
                            "ce:indexed-name": "Zhang Q."
                        }]
                    },
                    {
                        "affiliation": {
                            "@afid": "60073540",
                            "city": "Gonghshu District, Hangzhou",
                            "organization": {"$": "Zheijang Cancer Hospital"},
                            "affiliation-id": {"@afid": "60073540"},
                            "@affiliation-instance-id": "S2059702922001892-f0c29c0effcb34aa631ca69209fe771d",
                            "ce:source-text": "Zheijang Cancer Hospital, Gonghshu District, Hangzhou"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "X.",
                                "ce:initials": "X.",
                                "ce:surname": "Wang",
                                "ce:indexed-name": "Wang X."
                            },
                            "@seq": "7",
                            "@author-instance-id": "S2059702922001892-1bcb2af2e681ab3f9ebad7aac1e93052",
                            "ce:initials": "X.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wang",
                            "@auid": "57272906400",
                            "ce:indexed-name": "Wang X."
                        }]
                    },
                    {
                        "affiliation": {
                            "@afid": "60082502",
                            "city": "Yuexiu District, Guangzhou",
                            "organization": {"$": "Sun Yet-sen University Cancer Center"},
                            "affiliation-id": {"@afid": "60082502"},
                            "@affiliation-instance-id": "S2059702922001892-210f2d72410bb2d308ab19440e08e32a",
                            "ce:source-text": "Sun Yet-sen University Cancer Center, Yuexiu District, Guangzhou"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S.",
                                "ce:initials": "S.",
                                "ce:surname": "Wang",
                                "ce:indexed-name": "Wang S."
                            },
                            "@seq": "8",
                            "@author-instance-id": "S2059702922001892-61f64fd89f915f0f28715d09046b0236",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wang",
                            "@auid": "57852636600",
                            "ce:indexed-name": "Wang S."
                        }]
                    },
                    {
                        "affiliation": {
                            "@afid": "60108904",
                            "city": "Xuhui District, Shanghai",
                            "organization": {"$": "Fudan University Shanghai Cancer Center"},
                            "affiliation-id": {"@afid": "60108904"},
                            "@affiliation-instance-id": "S2059702922001892-0a871f8572180d8511e144a968c3d87a",
                            "ce:source-text": "Fudan University Shanghai Cancer Center, Xuhui District, Shanghai"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "Z.",
                                "ce:initials": "Z.",
                                "ce:surname": "Shao",
                                "ce:indexed-name": "Shao Z."
                            },
                            "@seq": "9",
                            "@author-instance-id": "S2059702922001892-7565cffcc9319d9f6073d359803bc34f",
                            "ce:initials": "Z.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Shao",
                            "@auid": "58276566800",
                            "ce:indexed-name": "Shao Z."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "address-part": "Hai-Dian District",
                            "@afid": "60008510",
                            "@country": "chn",
                            "city": "Beijing",
                            "organization": [
                                {"$": "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)"},
                                {"$": "Department of Breast Oncology"},
                                {"$": "Peking University Cancer Hospital & Institute"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60008510",
                                    "@dptid": "103473362"
                                },
                                {"@afid": "60001604"}
                            ],
                            "@affiliation-instance-id": "S2059702922001892-4d5ea53ad6640c39f37b93be82a10a35",
                            "ce:source-text": "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Hai-Dian District, Beijing, China",
                            "@dptid": "103473362"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "H.",
                                "ce:initials": "H.",
                                "ce:surname": "Li",
                                "ce:indexed-name": "Li H."
                            },
                            "@seq": "10",
                            "@author-instance-id": "S2059702922001892-fd71de3f842ed445fb6967d2904df3af",
                            "ce:initials": "H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Li",
                            "@auid": "57216801691",
                            "ce:indexed-name": "Li H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Indonesia",
                            "@afid": "114030941",
                            "@country": "idn",
                            "city": "Jakarta",
                            "organization": [
                                {"$": "MRCCC Siloam Semanggi Hospital"},
                                {"$": "Daerah Khusus Ibukota"}
                            ],
                            "affiliation-id": {"@afid": "114030941"},
                            "@affiliation-instance-id": "S2059702922001892-a7b723157bfa88e882e718d1c92f1332",
                            "ce:source-text": "MRCCC Siloam Semanggi Hospital, Daerah Khusus Ibukota, Jakarta, Indonesia"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "A.",
                                "ce:initials": "A.",
                                "ce:surname": "Rachman",
                                "ce:indexed-name": "Rachman A."
                            },
                            "@seq": "11",
                            "@author-instance-id": "S2059702922001892-b6ea9f75dfa150d28f0f30084c6469e7",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Rachman",
                            "@auid": "15056701600",
                            "ce:indexed-name": "Rachman A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "King Chulalongkorn Memorial Hospital"},
                                {"$": "Pathum Wan"}
                            ],
                            "affiliation-id": {"@afid": "60022183"},
                            "@affiliation-instance-id": "S2059702922001892-9652343b54b9f9f6fa4820b6a6ff6f99",
                            "ce:source-text": "King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok, Thailand"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "M.",
                                "ce:initials": "M.",
                                "ce:surname": "Vongsaisuwon",
                                "ce:indexed-name": "Vongsaisuwon M."
                            },
                            "@seq": "12",
                            "@author-instance-id": "S2059702922001892-500520e67ae5305e9018c944cdaccf8c",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Vongsaisuwon",
                            "@auid": "57202704043",
                            "ce:indexed-name": "Vongsaisuwon M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Switzerland",
                            "@afid": "60008201",
                            "@country": "che",
                            "city": "Basel",
                            "organization": {"$": "F. Hoffmann-La Roche"},
                            "affiliation-id": {"@afid": "60008201"},
                            "@affiliation-instance-id": "S2059702922001892-5d21071747c618d3ac8c8c53cc389757",
                            "ce:source-text": "F. Hoffmann-La Roche, Basel, Switzerland"
                        },
                        "author": [
                            {
                                "preferred-name": {
                                    "ce:given-name": "H.",
                                    "ce:initials": "H.",
                                    "ce:surname": "Liu",
                                    "ce:indexed-name": "Liu H."
                                },
                                "@seq": "13",
                                "@author-instance-id": "S2059702922001892-0fe8a0ea9b955e89375255d33592f6d0",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Liu",
                                "@auid": "56969980200",
                                "ce:indexed-name": "Liu H."
                            },
                            {
                                "preferred-name": {
                                    "ce:given-name": "S.",
                                    "ce:initials": "S.",
                                    "ce:surname": "Fear",
                                    "ce:indexed-name": "Fear S."
                                },
                                "@seq": "14",
                                "@author-instance-id": "S2059702922001892-db7f8c4ec64e20f9a9a2cb958573c5d6",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Fear",
                                "@auid": "57207874296",
                                "ce:indexed-name": "Fear S."
                            },
                            {
                                "preferred-name": {
                                    "ce:given-name": "C.",
                                    "ce:initials": "C.",
                                    "ce:surname": "Peña-Murillo",
                                    "ce:indexed-name": "Peña-Murillo C."
                                },
                                "@seq": "15",
                                "@author-instance-id": "S2059702922001892-aa8ba33da4fe3e4ae68b87465511bf73",
                                "ce:initials": "C.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Peña-Murillo",
                                "@auid": "57219235129",
                                "ce:indexed-name": "Pena-Murillo C."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Brazil",
                            "@afid": "60015760",
                            "@country": "bra",
                            "city": "Porto Alegre",
                            "organization": [
                                {"$": "Oncology Research Center HSL"},
                                {"$": "PUCRS"},
                                {"$": "Latin American Cooperative Oncology Group"}
                            ],
                            "affiliation-id": {
                                "@afid": "60015760",
                                "@dptid": "107703929"
                            },
                            "@affiliation-instance-id": "S2059702922001892-a4893018e7032f14dbb82cb917fab7db",
                            "ce:source-text": "Oncology Research Center HSL, PUCRS, Latin American Cooperative Oncology Group, Porto Alegre, Brazil",
                            "@dptid": "107703929"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "C.",
                                "ce:initials": "C.",
                                "ce:surname": "Barrios",
                                "ce:indexed-name": "Barrios C."
                            },
                            "@seq": "16",
                            "@author-instance-id": "S2059702922001892-e50ba06bee0272a7bd18722cfa94d346",
                            "ce:initials": "C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Barrios",
                            "@auid": "56594579000",
                            "ce:indexed-name": "Barrios C."
                        }]
                    }
                ],
                "citation-title": "Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer",
                "abstracts": "© 2022 The AuthorsBackground: KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC; NCT01702571). We report the final analysis of cohort 2 (Asia) within the context of published cohort 1 (Global) findings. Methods: Patients had HER2-positive, locally advanced, or metastatic BC progressing after chemotherapy and anti-HER2 therapy or ≤6 months after adjuvant therapy. The primary objective was to further evaluate T-DM1 (3.6 mg/kg, administered intravenously every 3 weeks) safety/tolerability, including the following adverse events of primary interest (AEPIs): grade ≥3 AEPIs (hepatic events, allergic reactions, thrombocytopenia, hemorrhage events), all grade ≥3 treatment-related AEs, and all-grade pneumonitis. Results: KAMILLA enrolled 2185 patients (cohort 1, n = 2003; cohort 2, n = 182) as of 31 July 2019. Of these, 2002 and 181 per cohort were treated and included in the safety population. Approximately 70% of patients had two or more previous treatment lines in the metastatic setting. Median T-DM1 exposure was 5.6 and 5.0 months per cohort; median follow-up was 20.6 and 15.1 months. The overall AEPI rate was higher in cohort 2 (93/181; 51.4%) versus cohort 1 (462/2002; 23.1%), mostly driven by a higher grade ≥3 thrombocytopenia rate in cohort 2. In cohort 2, grade ≥3 thrombocytopenia was not associated with grade ≥3 hemorrhagic events and most (128/138) fully resolved. Grade ≥3 treatment-related AEPI rates were 18.4% (cohort 1) and 48.6% (cohort 2), the latter mainly due to thrombocytopenia. Any-grade pneumonitis rates were 1.0% and 2.2%. No new safety signals were identified. Median (95% confidence interval) progression-free survival was 6.8 months (5.8-7.6 months) and 5.7 months (5.5-7.0 months) in cohorts 1 and 2, respectively; median overall survival was 27.2 months (25.5-28.7 months) and 29.5 months (21.1 months to non-estimable). In both cohorts, median progression-free survival and overall survival decreased with increasing prior therapy lines. Conclusions: Cohort 2 results aligned with previous findings in Asian patients, supporting the manageable safety profile and use of T-DM1 in advanced BC.",
                "correspondence": {
                    "affiliation": {
                        "country": "Germany",
                        "address-part": "Marchioninistr. 15",
                        "postal-code": "81377",
                        "@country": "deu",
                        "city": "Munich",
                        "organization": [
                            {"$": "University Hospital Munich"},
                            {"$": "Department of Obstetrics and Gynecology"},
                            {"$": "Breast Center and CCC Munich"},
                            {"$": "LMU"}
                        ]
                    },
                    "person": {
                        "ce:initials": "R.",
                        "ce:surname": "Wuerstlein",
                        "ce:indexed-name": "Wuerstlein R."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "Asia",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "HER2-positive metastatic breast cancer",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "KAMILLA",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "safety",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "trastuzumab emtansine (TDM-1)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://www.journals.elsevier.com/esmo-open/",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "volisspag": {"voliss": {
                        "@volume": "7",
                        "@issue": "5"
                    }},
                    "@type": "j",
                    "sourcetitle": "ESMO Open",
                    "publicationdate": {
                        "month": "10",
                        "year": "2022",
                        "date-text": "October 2022",
                        "day": "01"
                    },
                    "sourcetitle-abbrev": "ESMO Open",
                    "@country": "gbr",
                    "issn": {
                        "$": "20597029",
                        "@type": "electronic"
                    },
                    "publicationyear": {"@first": "2022"},
                    "publisher": {"publishername": "Elsevier B.V."},
                    "article-number": "100561",
                    "@srcid": "21100873339"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2730"},
                                {"$": "1306"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": [
                                {"$": "MEDI"},
                                {"$": "BIOC"}
                            ]
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "137632-09-8",
                                    "chemical-name": "epidermal growth factor receptor 2"
                                },
                                {
                                    "cas-registry-number": "35846-53-8",
                                    "chemical-name": "maytansine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "180288-69-1"},
                                        {"$": "1446410-98-5"}
                                    ],
                                    "chemical-name": "trastuzumab"
                                },
                                {
                                    "cas-registry-number": "1018448-65-1",
                                    "chemical-name": "trastuzumab emtansine"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Ado-Trastuzumab Emtansine"},
                                {"chemical-name": "Antibodies, Monoclonal, Humanized"},
                                {"chemical-name": "Maytansine"},
                                {"chemical-name": "Receptor, ErbB-2"},
                                {"chemical-name": "Trastuzumab"}
                            ]
                        }
                    ]}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "This work was supported by F. Hoffmann-La Roche, Switzerland (no grant number). F. Hoffmann-La Roche participated in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.The authors are grateful to the patients and families for their participation in the KAMILLLA study, as well as the KAMILLA study investigators. For a full list of KAMILLA study investigators, please see Montemurro et al. Eur J Cancer 2019.11 Support for third-party writing assistance was provided by Sachi Yim, PhD, of Ashfield MedComms, an Ashfield Health Company, and funded by F. Hoffmann-La Roche. Qualified researchers may request access to de-identified patient-level data through the Clinical Study Data Request platform (www.clinicalstudydatarequest.com) and will be provided with accompanying clinical study documentation (protocol and any associated amendments, annotated case report form, reporting and analysis plan, dataset specifications, clinical study report). Researchers requesting access to clinical study documentation only can do so via the following link: http://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing/clinical_study_documents_request_form.htm, Documents are made available on application, per scope and timing criteria as published on the Clinical Study Data Request platform.",
                        "@xml:lang": "eng"
                    },
                    "grant": [
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "F. Hoffmann-La Roche"
                            },
                            "grant-agency-id": "100007013"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "F. Hoffmann-La Roche"
                            },
                            "grant-agency-id": "100007013"
                        }
                    ]
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"},
                    {"$": "MEDL"}
                ],
                "history": {"date-created": {
                    "@day": "11",
                    "@year": "2022",
                    "@timestamp": "BST 08:30:36",
                    "@month": "09"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2020078045",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "942714391",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220804541",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "20222655136",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20223103106",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "85137385802",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85137385802",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "638990065",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "36084395",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "911675116",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:pii": "S2059702922001892",
                    "ce:ern": "pii:S2059702922001892",
                    "ce:doi": "10.1016/j.esmoop.2022.100561"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "32",
                "reference": [
                    {
                        "ref-fulltext": "Kadcyla® prescribing information: Genentech, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf, 2019. (Accessed 16 July 2021)",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Kadcyla® prescribing information: Genentech, Inc"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib1",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137384764",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 16 July 2021)"
                        },
                        "ce:source-text": "Kadcyla® prescribing information: Genentech, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf; 2019. Accessed July 16, 2021."
                    },
                    {
                        "ref-fulltext": "Kadcyla® summary of product characteristics. Available at https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. (Accessed 6 August 2021)",
                        "@id": "2",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Kadcyla® summary of product characteristics"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib2",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137383801",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 6 August 2021)"
                        },
                        "ce:source-text": "Kadcyla® summary of product characteristics. Available at https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Accessed August 6, 2021."
                    },
                    {
                        "ref-fulltext": "Barok, M., Joensuu, H., Isola, J., Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res, 16, 2014, 209.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine: mechanisms of action and drug resistance"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib3",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84896776546",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "16"},
                                "pagerange": {"@first": "209"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Barok",
                                    "ce:indexed-name": "Barok M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Joensuu",
                                    "ce:indexed-name": "Joensuu H."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Isola",
                                    "ce:indexed-name": "Isola J."
                                }
                            ]},
                            "ref-sourcetitle": "Breast Cancer Res"
                        },
                        "ce:source-text": "Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209."
                    },
                    {
                        "ref-fulltext": "Verma, S., Miles, D., Gianni, L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783\u20131791.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine for HER2-positive advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib4",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84868520609",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "367"},
                                "pagerange": {
                                    "@first": "1783",
                                    "@last": "1791"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Verma",
                                        "ce:indexed-name": "Verma S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Miles",
                                        "ce:indexed-name": "Miles D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gianni",
                                        "ce:indexed-name": "Gianni L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791."
                    },
                    {
                        "ref-fulltext": "Krop, I.E., Kim, S.B., González-Martín, A., et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label, phase 3 trial. Lancet Oncol 15 (2014), 689\u2013699.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib5",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84901639476",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "15"},
                                "pagerange": {
                                    "@first": "689",
                                    "@last": "699"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Krop",
                                        "ce:indexed-name": "Krop I.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "González-Martín",
                                        "ce:indexed-name": "Gonzalez-Martin A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label, phase 3 trial. Lancet Oncol. 2014;15:689-699."
                    },
                    {
                        "ref-fulltext": "Krop, I.E., Kim, S.B., Martin, A.G., et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 18 (2017), 743\u2013754.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib6",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85019974512",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "18"},
                                "pagerange": {
                                    "@first": "743",
                                    "@last": "754"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Krop",
                                        "ce:indexed-name": "Krop I.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin A.G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743-754."
                    },
                    {
                        "ref-fulltext": "Vici, P., Pizzuti, L., Michelotti, A., et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget 8 (2017), 56921\u201356931.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib7",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85029080148",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "56921",
                                    "@last": "56931"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Vici",
                                        "ce:indexed-name": "Vici P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Pizzuti",
                                        "ce:indexed-name": "Pizzuti L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Michelotti",
                                        "ce:indexed-name": "Michelotti A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncotarget"
                        },
                        "ce:source-text": "Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8:56921-56931."
                    },
                    {
                        "ref-fulltext": "Conte, B., Fabi, A., Poggio, F., et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin Breast Cancer 20 (2020), e181\u2013e187.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib8",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082460205",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "e181",
                                    "@last": "e187"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Conte",
                                        "ce:indexed-name": "Conte B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Fabi",
                                        "ce:indexed-name": "Fabi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Poggio",
                                        "ce:indexed-name": "Poggio F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Breast Cancer"
                        },
                        "ce:source-text": "Conte B, Fabi A, Poggio F, et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin Breast Cancer. 2020;20:e181-e187."
                    },
                    {
                        "ref-fulltext": "Bahçeci, A., Paydaş, S., Ak, N., et al. Efficacy and safety of trastuzumab emtansine in HER2 positive metastatic breast cancer: real-world experience. Cancer Invest 39 (2021), 473\u2013481.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of trastuzumab emtansine in HER2 positive metastatic breast cancer: real-world experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib9",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85107585337",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "39"},
                                "pagerange": {
                                    "@first": "473",
                                    "@last": "481"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bahçeci",
                                        "ce:indexed-name": "Bahceci A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Paydaş",
                                        "ce:indexed-name": "Paydas S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Ak",
                                        "ce:indexed-name": "Ak N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Invest"
                        },
                        "ce:source-text": "Bahceci A, Paydas S, Ak N, et al. Efficacy and safety of trastuzumab emtansine in HER2 positive metastatic breast cancer: real-world experience. Cancer Invest. 2021;39:473-481."
                    },
                    {
                        "ref-fulltext": "Hardy-Werbin, M., Quiroga, V., Cirauqui, B., et al. Real-world data on T-DM1 efficacy \u2013 results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep, 9, 2019, 12760.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Real-world data on T-DM1 efficacy \u2013 results of a single-center retrospective study of HER2-positive breast cancer patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib10",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85071737247",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {"@first": "12760"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Hardy-Werbin",
                                        "ce:indexed-name": "Hardy-Werbin M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Quiroga",
                                        "ce:indexed-name": "Quiroga V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Cirauqui",
                                        "ce:indexed-name": "Cirauqui B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Rep"
                        },
                        "ce:source-text": "Hardy-Werbin M, Quiroga V, Cirauqui B, et al. Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep. 2019;9:12760."
                    },
                    {
                        "ref-fulltext": "Montemurro, F., Ellis, P., Anton, A., et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer 109 (2019), 92\u2013102.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib11",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85060614919",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "109"},
                                "pagerange": {
                                    "@first": "92",
                                    "@last": "102"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Montemurro",
                                        "ce:indexed-name": "Montemurro F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Ellis",
                                        "ce:indexed-name": "Ellis P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Anton",
                                        "ce:indexed-name": "Anton A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Montemurro F, Ellis P, Anton A, et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019;109:92-102."
                    },
                    {
                        "ref-fulltext": "Dieras, V., Harbeck, N., Budd, G.T., et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 32 (2014), 2750\u20132757.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib12",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84906819100",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "32"},
                                "pagerange": {
                                    "@first": "2750",
                                    "@last": "2757"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Dieras",
                                        "ce:indexed-name": "Dieras V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Harbeck",
                                        "ce:indexed-name": "Harbeck N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Budd",
                                        "ce:indexed-name": "Budd G.T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Dieras V, Harbeck N, Budd GT, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014;32:2750-2757."
                    },
                    {
                        "ref-fulltext": "National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v4.0. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_Applications/ctc.htm#ctc_40. (Accessed 13 July 2021)",
                        "@id": "13",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://ctep.cancer.gov/protocoldevelopment/electronic_Applications/ctc.htm#ctc_40",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Common Terminology Criteria for Adverse Events (CTCAE), v4.0"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib13",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "12744281454",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 13 July 2021)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "National Cancer Institute",
                                "ce:indexed-name": "National Cancer Institute"
                            }}
                        },
                        "ce:source-text": "National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v4.0. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_Applications/ctc.htm#ctc_40. Accessed July 13, 2021."
                    },
                    {
                        "ref-fulltext": "Im, S., Park, I., Sohn, J.H., et al. Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase III EMILIA study. Ann Oncol 32 (2021), S457\u2013S515.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase III EMILIA study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib14",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137391170",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "32"},
                                "pagerange": {
                                    "@first": "S457",
                                    "@last": "S515"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Sohn",
                                        "ce:indexed-name": "Sohn J.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Im S, Park I, Sohn JH, et al. Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase III EMILIA study. Ann Oncol. 2021;32:S457-S515."
                    },
                    {
                        "ref-fulltext": "Modi, N., Sorich, M.J., Rowland, A., et al. Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine. Clin Breast Cancer 20 (2020), e220\u2013e228.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib15",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85076992637",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "e220",
                                    "@last": "e228"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Modi",
                                        "ce:indexed-name": "Modi N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Sorich",
                                        "ce:indexed-name": "Sorich M.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Rowland",
                                        "ce:indexed-name": "Rowland A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Breast Cancer"
                        },
                        "ce:source-text": "Modi N, Sorich MJ, Rowland A, et al. Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine. Clin Breast Cancer. 2020;20:e220-e228."
                    },
                    {
                        "ref-fulltext": "Hackshaw, M.D., Danysh, H.E., Singh, J., et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat 183 (2020), 23\u201339.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib16",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087365971",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "183"},
                                "pagerange": {
                                    "@first": "23",
                                    "@last": "39"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Hackshaw",
                                        "ce:indexed-name": "Hackshaw M.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Danysh",
                                        "ce:indexed-name": "Danysh H.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Singh",
                                        "ce:indexed-name": "Singh J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183:23-39."
                    },
                    {
                        "ref-fulltext": "Modi, S., Saura, C., Yamashita, T., et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382 (2020), 610\u2013621.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Trastuzumab deruxtecan in previously treated HER2-positive breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib17",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077471546",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "382"},
                                "pagerange": {
                                    "@first": "610",
                                    "@last": "621"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Modi",
                                        "ce:indexed-name": "Modi S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Saura",
                                        "ce:indexed-name": "Saura C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Yamashita",
                                        "ce:indexed-name": "Yamashita T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610-621."
                    },
                    {
                        "ref-fulltext": "von Minckwitz, G., Huang, C.S., Mano, M.S., et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380 (2019), 617\u2013628.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine for residual invasive HER2-positive breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib18",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85059540229",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "380"},
                                "pagerange": {
                                    "@first": "617",
                                    "@last": "628"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "von Minckwitz",
                                        "ce:indexed-name": "von Minckwitz G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Mano",
                                        "ce:indexed-name": "Mano M.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617-628."
                    },
                    {
                        "ref-fulltext": "Cortés, J., Kim, S., Chung, W., et al. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. 2021, LBA1 Presented at the European Society for Medical Oncology conference.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib19",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137393438",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "LBA1 Presented at the European Society for Medical Oncology conference",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cortés",
                                        "ce:indexed-name": "Cortes J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Chung",
                                        "ce:indexed-name": "Chung W."
                                    }
                                ],
                                "et-al": null
                            }
                        },
                        "ce:source-text": "Cortes J, Kim S, Chung W, et al. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Presented at the European Society for Medical Oncology conference. 2021; LBA1."
                    },
                    {
                        "ref-fulltext": "Montemurro, F., Delaloge, S., Barrios, C.H., et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 31 (2020), 1350\u20131358.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib20",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088803138",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "1350",
                                    "@last": "1358"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Montemurro",
                                        "ce:indexed-name": "Montemurro F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Delaloge",
                                        "ce:indexed-name": "Delaloge S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Barrios",
                                        "ce:indexed-name": "Barrios C.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31:1350-1358."
                    },
                    {
                        "ref-fulltext": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Guidelines V.8.2021. © National Comprehensive Cancer Network, Inc, 2021 All rights reserved. Accessed February 17, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib21",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137401015",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "All rights reserved. Accessed February 17, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way",
                            "ref-sourcetitle": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Guidelines V.8.2021. © National Comprehensive Cancer Network, Inc"
                        },
                        "ce:source-text": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Guidelines V.8.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 17, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."
                    },
                    {
                        "ref-fulltext": "Cardoso, F., Paluch-Shimon, S., Senkus, E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31 (2020), 1623\u20131649.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib22",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094163853",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {
                                    "@first": "1623",
                                    "@last": "1649"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Cardoso",
                                        "ce:indexed-name": "Cardoso F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Paluch-Shimon",
                                        "ce:indexed-name": "Paluch-Shimon S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Senkus",
                                        "ce:indexed-name": "Senkus E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623-1649."
                    },
                    {
                        "ref-fulltext": "Thill, M., Friedrich, M., Kolberg-Liedtke, C., et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021. Breast Care (Basel) 16 (2021), 228\u2013235.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib23",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85107646868",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "16"},
                                "pagerange": {
                                    "@first": "228",
                                    "@last": "235"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Thill",
                                        "ce:indexed-name": "Thill M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Friedrich",
                                        "ce:indexed-name": "Friedrich M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Kolberg-Liedtke",
                                        "ce:indexed-name": "Kolberg-Liedtke C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Care (Basel)"
                        },
                        "ce:source-text": "Thill M, Friedrich M, Kolberg-Liedtke C, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021. Breast Care (Basel). 2021;16:228-235."
                    },
                    {
                        "ref-fulltext": "Tykerb® prescribing information: Novartis Pharmaceuticals Corporation. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf, 2018. (Accessed 16 July 2021)",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Tykerb® prescribing information: Novartis Pharmaceuticals Corporation"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib24",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137396259",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 16 July 2021)"
                        },
                        "ce:source-text": "Tykerb® prescribing information: Novartis Pharmaceuticals Corporation. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf; 2018. Accessed July 16, 2021."
                    },
                    {
                        "ref-fulltext": "Nerlynx® prescribing information: Puma Biotechology, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf, 2020. (Accessed 16 July 2021)",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Nerlynx® prescribing information: Puma Biotechology, Inc"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib25",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137403235",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 16 July 2021)"
                        },
                        "ce:source-text": "Nerlynx® prescribing information: Puma Biotechology, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf; 2020. Accessed July 16, 2021."
                    },
                    {
                        "ref-fulltext": "TukysaTMprescribing information: Seattle Genetics, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf, 2020. (Accessed 9 August 2021)",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "TukysaTMprescribing information: Seattle Genetics, Inc"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib26",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137392191",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 9 August 2021)"
                        },
                        "ce:source-text": "TukysaTM prescribing information: Seattle Genetics, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf; 2020. Accessed August 9, 2021."
                    },
                    {
                        "ref-fulltext": "Saura, C., Oliveira, M., Feng, Y.H., et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 38 (2020), 3138\u20133149.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib27",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088803559",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "3138",
                                    "@last": "3149"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Saura",
                                        "ce:indexed-name": "Saura C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Oliveira",
                                        "ce:indexed-name": "Oliveira M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Feng",
                                        "ce:indexed-name": "Feng Y.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138-3149."
                    },
                    {
                        "ref-fulltext": "Murthy, R.K., Loi, S., Okines, A., et al. Tucatinib, trastuzumab, and caepcitabine for HER2-positive metastatic breast cancer. N Engl J Med 13 (2020), 597\u2013609.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Tucatinib, trastuzumab, and caepcitabine for HER2-positive metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib28",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077435898",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {
                                    "@first": "597",
                                    "@last": "609"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Murthy",
                                        "ce:indexed-name": "Murthy R.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Loi",
                                        "ce:indexed-name": "Loi S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Okines",
                                        "ce:indexed-name": "Okines A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and caepcitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;13:597-609."
                    },
                    {
                        "ref-fulltext": "Borges, V.F., Ferrario, C., Aucoin, N., et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol 4 (2018), 1214\u20131220.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib29",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052913791",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "1214",
                                    "@last": "1220"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Borges",
                                        "ce:indexed-name": "Borges V.F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Ferrario",
                                        "ce:indexed-name": "Ferrario C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Aucoin",
                                        "ce:indexed-name": "Aucoin N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Borges VF, Ferrario C, Aucoin N, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4:1214-1220."
                    },
                    {
                        "ref-fulltext": "Blair, H.A., Pyrotinib: first global approval. Drugs 78 (2018), 1751\u20131755.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Pyrotinib: first global approval"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib30",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85055729241",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "78"},
                                "pagerange": {
                                    "@first": "1751",
                                    "@last": "1755"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "H.A.",
                                "@_fa": "true",
                                "ce:surname": "Blair",
                                "ce:indexed-name": "Blair H.A."
                            }]},
                            "ref-sourcetitle": "Drugs"
                        },
                        "ce:source-text": "Blair HA. Pyrotinib: first global approval. Drugs. 2018;78:1751-1755."
                    },
                    {
                        "ref-fulltext": "Ma, F., Ouyang, Q., Li, W., et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and /or trastuzumab: a randomized/phase II study. J Clin Oncol 37 (2019), 2610\u20132619.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and /or trastuzumab: a randomized/phase II study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib31",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072993966",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "37"},
                                "pagerange": {
                                    "@first": "2610",
                                    "@last": "2619"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Ouyang",
                                        "ce:indexed-name": "Ouyang Q."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and /or trastuzumab: a randomized/phase II study. J Clin Oncol. 2019;37:2610-2619."
                    },
                    {
                        "ref-fulltext": "Enhertu® prescribing information: Daiichi Sankyo, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf, 2021. (Accessed 2 December 2021)",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Enhertu® prescribing information: Daiichi Sankyo, Inc"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib32",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137392077",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 2 December 2021)"
                        },
                        "ce:source-text": "Enhertu® prescribing information: Daiichi Sankyo, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf; 2021. Accessed December 02, 2021."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Shanghai",
            "@id": "60108904",
            "affilname": "Fudan University Shanghai Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60082502",
            "affilname": "Sun Yat-Sen University Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hangzhou",
            "@id": "60073540",
            "affilname": "Zhejiang Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073540",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Candiolo",
            "@id": "60070526",
            "affilname": "Candiolo Cancer Institute-FPO- IRCCS",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070526",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Villejuif",
            "@id": "60027386",
            "affilname": "Institut de Cancerologie Gustave Roussy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027386",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Zaragoza",
            "@id": "60022336",
            "affilname": "Hospital Miguel Servet",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022336",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Harbin",
            "@id": "60021615",
            "affilname": "Harbin Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021615",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Porto Alegre",
            "@id": "60015760",
            "affilname": "Pontifícia Universidade Católica do Rio Grande do Sul",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015760",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "London",
            "@id": "60009797",
            "affilname": "Guy's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009797",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60008510",
            "affilname": "Beijing Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008510",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60008201",
            "affilname": "F. Hoffmann-La Roche AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Munich",
            "@id": "60000291",
            "affilname": "Klinikum der Universität München",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000291",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Jakarta",
            "@id": "114030941",
            "affilname": "MRCCC Siloam Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/114030941",
            "affiliation-country": "Indonesia"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85137385802",
        "dc:description": "Background: KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC; NCT01702571). We report the final analysis of cohort 2 (Asia) within the context of published cohort 1 (Global) findings. Methods: Patients had HER2-positive, locally advanced, or metastatic BC progressing after chemotherapy and anti-HER2 therapy or ≤6 months after adjuvant therapy. The primary objective was to further evaluate T-DM1 (3.6 mg/kg, administered intravenously every 3 weeks) safety/tolerability, including the following adverse events of primary interest (AEPIs): grade ≥3 AEPIs (hepatic events, allergic reactions, thrombocytopenia, hemorrhage events), all grade ≥3 treatment-related AEs, and all-grade pneumonitis. Results: KAMILLA enrolled 2185 patients (cohort 1, n = 2003; cohort 2, n = 182) as of 31 July 2019. Of these, 2002 and 181 per cohort were treated and included in the safety population. Approximately 70% of patients had two or more previous treatment lines in the metastatic setting. Median T-DM1 exposure was 5.6 and 5.0 months per cohort; median follow-up was 20.6 and 15.1 months. The overall AEPI rate was higher in cohort 2 (93/181; 51.4%) versus cohort 1 (462/2002; 23.1%), mostly driven by a higher grade ≥3 thrombocytopenia rate in cohort 2. In cohort 2, grade ≥3 thrombocytopenia was not associated with grade ≥3 hemorrhagic events and most (128/138) fully resolved. Grade ≥3 treatment-related AEPI rates were 18.4% (cohort 1) and 48.6% (cohort 2), the latter mainly due to thrombocytopenia. Any-grade pneumonitis rates were 1.0% and 2.2%. No new safety signals were identified. Median (95% confidence interval) progression-free survival was 6.8 months (5.8-7.6 months) and 5.7 months (5.5-7.0 months) in cohorts 1 and 2, respectively; median overall survival was 27.2 months (25.5-28.7 months) and 29.5 months (21.1 months to non-estimable). In both cohorts, median progression-free survival and overall survival decreased with increasing prior therapy lines. Conclusions: Cohort 2 results aligned with previous findings in Asian patients, supporting the manageable safety profile and use of T-DM1 in advanced BC.",
        "pubmed-id": "36084395",
        "prism:coverDate": "2022-10-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85137385802",
        "dc:creator": {"author": [{
            "preferred-name": {
                "ce:given-name": "R.",
                "ce:initials": "R.",
                "ce:surname": "Wuerstlein",
                "ce:indexed-name": "Wuerstlein R."
            },
            "@seq": "1",
            "ce:initials": "R.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60000291",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000291"
            },
            "ce:surname": "Wuerstlein",
            "@auid": "35489598700",
            "author-url": "https://api.elsevier.com/content/author/author_id/35489598700",
            "ce:indexed-name": "Wuerstlein R."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85137385802"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137385802&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85137385802&origin=inward"
            }
        ],
        "source-id": "21100873339",
        "pii": "S2059702922001892",
        "citedby-count": "3",
        "prism:volume": "7",
        "subtype": "ar",
        "dc:title": "Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer",
        "openaccess": "1",
        "prism:issn": "20597029",
        "publishercopyright": "© 2022 The Authors",
        "article-number": "100561",
        "prism:issueIdentifier": "5",
        "subtypeDescription": "Article",
        "prism:publicationName": "ESMO Open",
        "openaccessFlag": "true",
        "prism:doi": "10.1016/j.esmoop.2022.100561",
        "dc:identifier": "SCOPUS_ID:85137385802",
        "dc:publisher": "Elsevier B.V."
    },
    "idxterms": {"mainterm": [
        {
            "$": "Ado-Trastuzumab Emtansine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Antibodies, Monoclonal, Humanized",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Breast Neoplasms",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Maytansine",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Receptor, ErbB-2",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Trastuzumab",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "Asia"
        },
        {
            "@_fa": "true",
            "$": "HER2-positive metastatic breast cancer"
        },
        {
            "@_fa": "true",
            "$": "KAMILLA"
        },
        {
            "@_fa": "true",
            "$": "safety"
        },
        {
            "@_fa": "true",
            "$": "trastuzumab emtansine (TDM-1)"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ]},
    "authors": {"author": [
        {
            "preferred-name": {
                "ce:given-name": "R.",
                "ce:initials": "R.",
                "ce:surname": "Wuerstlein",
                "ce:indexed-name": "Wuerstlein R."
            },
            "@seq": "1",
            "ce:initials": "R.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60000291",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000291"
            },
            "ce:surname": "Wuerstlein",
            "@auid": "35489598700",
            "author-url": "https://api.elsevier.com/content/author/author_id/35489598700",
            "ce:indexed-name": "Wuerstlein R."
        },
        {
            "preferred-name": {
                "ce:given-name": "P.",
                "ce:initials": "P.",
                "ce:surname": "Ellis",
                "ce:indexed-name": "Ellis P."
            },
            "@seq": "2",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009797",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009797"
            },
            "ce:surname": "Ellis",
            "@auid": "16214959300",
            "author-url": "https://api.elsevier.com/content/author/author_id/16214959300",
            "ce:indexed-name": "Ellis P."
        },
        {
            "preferred-name": {
                "ce:given-name": "F.",
                "ce:initials": "F.",
                "ce:surname": "Montemurro",
                "ce:indexed-name": "Montemurro F."
            },
            "@seq": "3",
            "ce:initials": "F.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60070526",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070526"
            },
            "ce:surname": "Montemurro",
            "@auid": "35187447200",
            "author-url": "https://api.elsevier.com/content/author/author_id/35187447200",
            "ce:indexed-name": "Montemurro F."
        },
        {
            "preferred-name": {
                "ce:given-name": "A.",
                "ce:initials": "A.",
                "ce:surname": "Antón Torres",
                "ce:indexed-name": "Antón Torres A."
            },
            "@seq": "4",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60022336",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022336"
            },
            "ce:surname": "Antón Torres",
            "@auid": "6602294525",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602294525",
            "ce:indexed-name": "Anton Torres A."
        },
        {
            "preferred-name": {
                "ce:given-name": "S.",
                "ce:initials": "S.",
                "ce:surname": "Delaloge",
                "ce:indexed-name": "Delaloge S."
            },
            "@seq": "5",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60027386",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027386"
            },
            "ce:surname": "Delaloge",
            "@auid": "6701521265",
            "author-url": "https://api.elsevier.com/content/author/author_id/6701521265",
            "ce:indexed-name": "Delaloge S."
        },
        {
            "preferred-name": {
                "ce:given-name": "Q.",
                "ce:initials": "Q.",
                "ce:surname": "Zhang",
                "ce:indexed-name": "Zhang Q."
            },
            "@seq": "6",
            "ce:initials": "Q.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60021615",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021615"
            },
            "ce:surname": "Zhang",
            "@auid": "58374985400",
            "author-url": "https://api.elsevier.com/content/author/author_id/58374985400",
            "ce:indexed-name": "Zhang Q."
        },
        {
            "preferred-name": {
                "ce:given-name": "X.",
                "ce:initials": "X.",
                "ce:surname": "Wang",
                "ce:indexed-name": "Wang X."
            },
            "@seq": "7",
            "ce:initials": "X.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60073540",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073540"
            },
            "ce:surname": "Wang",
            "@auid": "57272906400",
            "author-url": "https://api.elsevier.com/content/author/author_id/57272906400",
            "ce:indexed-name": "Wang X."
        },
        {
            "preferred-name": {
                "ce:given-name": "S.",
                "ce:initials": "S.",
                "ce:surname": "Wang",
                "ce:indexed-name": "Wang S."
            },
            "@seq": "8",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60082502",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502"
            },
            "ce:surname": "Wang",
            "@auid": "57852636600",
            "author-url": "https://api.elsevier.com/content/author/author_id/57852636600",
            "ce:indexed-name": "Wang S."
        },
        {
            "preferred-name": {
                "ce:given-name": "Z.",
                "ce:initials": "Z.",
                "ce:surname": "Shao",
                "ce:indexed-name": "Shao Z."
            },
            "@seq": "9",
            "ce:initials": "Z.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60108904",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904"
            },
            "ce:surname": "Shao",
            "@auid": "58276566800",
            "author-url": "https://api.elsevier.com/content/author/author_id/58276566800",
            "ce:indexed-name": "Shao Z."
        },
        {
            "preferred-name": {
                "ce:given-name": "H.",
                "ce:initials": "H.",
                "ce:surname": "Li",
                "ce:indexed-name": "Li H."
            },
            "@seq": "10",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60008510",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008510"
            },
            "ce:surname": "Li",
            "@auid": "57216801691",
            "author-url": "https://api.elsevier.com/content/author/author_id/57216801691",
            "ce:indexed-name": "Li H."
        },
        {
            "preferred-name": {
                "ce:given-name": "A.",
                "ce:initials": "A.",
                "ce:surname": "Rachman",
                "ce:indexed-name": "Rachman A."
            },
            "@seq": "11",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "114030941",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/114030941"
            },
            "ce:surname": "Rachman",
            "@auid": "15056701600",
            "author-url": "https://api.elsevier.com/content/author/author_id/15056701600",
            "ce:indexed-name": "Rachman A."
        },
        {
            "preferred-name": {
                "ce:given-name": "M.",
                "ce:initials": "M.",
                "ce:surname": "Vongsaisuwon",
                "ce:indexed-name": "Vongsaisuwon M."
            },
            "@seq": "12",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60022183",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
            },
            "ce:surname": "Vongsaisuwon",
            "@auid": "57202704043",
            "author-url": "https://api.elsevier.com/content/author/author_id/57202704043",
            "ce:indexed-name": "Vongsaisuwon M."
        },
        {
            "preferred-name": {
                "ce:given-name": "H.",
                "ce:initials": "H.",
                "ce:surname": "Liu",
                "ce:indexed-name": "Liu H."
            },
            "@seq": "13",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60008201",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201"
            },
            "ce:surname": "Liu",
            "@auid": "56969980200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56969980200",
            "ce:indexed-name": "Liu H."
        },
        {
            "preferred-name": {
                "ce:given-name": "S.",
                "ce:initials": "S.",
                "ce:surname": "Fear",
                "ce:indexed-name": "Fear S."
            },
            "@seq": "14",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60008201",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201"
            },
            "ce:surname": "Fear",
            "@auid": "57207874296",
            "author-url": "https://api.elsevier.com/content/author/author_id/57207874296",
            "ce:indexed-name": "Fear S."
        },
        {
            "preferred-name": {
                "ce:given-name": "C.",
                "ce:initials": "C.",
                "ce:surname": "Peña-Murillo",
                "ce:indexed-name": "Peña-Murillo C."
            },
            "@seq": "15",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60008201",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201"
            },
            "ce:surname": "Peña-Murillo",
            "@auid": "57219235129",
            "author-url": "https://api.elsevier.com/content/author/author_id/57219235129",
            "ce:indexed-name": "Pena-Murillo C."
        },
        {
            "preferred-name": {
                "ce:given-name": "C.",
                "ce:initials": "C.",
                "ce:surname": "Barrios",
                "ce:indexed-name": "Barrios C."
            },
            "@seq": "16",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015760",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015760"
            },
            "ce:surname": "Barrios",
            "@auid": "56594579000",
            "author-url": "https://api.elsevier.com/content/author/author_id/56594579000",
            "ce:indexed-name": "Barrios C."
        }
    ]}
}}